Bristol Myers Squibb, an American multinational pharmaceutical company, completed the acquisition of Turning Point Therapeutics, a clinical-stage precision oncology company, for $4.1bn. "The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset. With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile," Giovanni Caforio, Bristol Myers Squibb Chairman and CEO.